"Funding Forums" Address Venture Capital and Government Funding Opportunities
WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- More than 60 innovative medical technology companies have been competitively selected to present company profiles before potential investors, partners and industry stakeholders, October 19 and 20 at AdvaMed 2010: The MedTech Conference. Selected companies represent innovation at all stages of development from various medical device sectors, and come from across the United States, Austria, Canada, Chile, Israel, Luxembourg, Switzerland and the United Kingdom. New this year are 20 company presentations from Coulter Foundation Translational Research Partnership Universities and two "Funding Forums" to highlight venture capital and government funding opportunities for emerging growth and established companies.
"We have selected a diverse group of companies with technologies that range from addressing traumatic brain injuries with medical neurotechnology to photonic tumor therapy and everything in-between," said Etienne Lagace, a Principal of Inovia Healthcare Ventures of Canada and a member of the AdvaMed 2010 company presentation selection committee. "These presentations and funding forums will provide companies with insights into the latest and most innovative technologies of today and tomorrow, as well as the funding opportunities available to develop these new, life saving and life changing medical devices. As an investor and an industry stakeholder, I look forward to hearing from all the companies and academic entrepreneurs."
AdvaMed 2010 presenting companies include the following:
4ibio, Pickering, Ontario, Canada
20/20 GeneSystems, Inc., Rockville, Maryland
Activiews, Inc., Lynnfield, Massachusetts
Advanced Dental Technology, Richmond, Virginia
Altrika, Inc. Sheffield, United Kingdom
Alverix, Inc., San Jose, California
AMES Technology, Inc., Portland, Oregon
Avancen MOD Corporation, Mount Pleasant, South Carolina
Biocompatibles International plc., Farnham, United Kingdom
BrainScope Company, Inc., Bethesda, Maryland
Calgary Scientific Inc., Calgary, Alberta, Canada
CerviLenz, Inc, Chagrin Falls, Ohio
Circuport, Inc., Morristown, New Jersey
Claro Scientific, St. Petersburg, Florida
Cohera Medical, Inc., Pittsburgh, Pennsylvania
CogniSens, Montreal, Quebec, Canada
ConvaTec Inc., Skillman, New Jersey
CSA Medical, Baltimore, Maryland
CytoPherx, Inc, Ann Arbor, Michigan
CytoSorbents Corporation, Monmouth Junction, New Jersey
DioGenix, Gaithersburg, Maryland
eSight Corporation, Ottawa, Ontario, Canada
Echometrix, Madison, Wisconsin
EGI, Eugene, Oregon
Endosense SA, Geneva, Switzerland
Endomimetrics, Birmingham, Alabama
Flowsense Medical Ltd., Misgav, Israel
GeneEx, Inc., Hialech, Florida
Hadasit Medical Research Services & Development Ltd., Jerusalem, Israel
Healionics Corporation, Seattle, Washington
Healthpoint, Ltd., Fort Worth, Texas
Interface Biologics, Toronto, Ontario, Canada
Jabil, Inc., St. Petersburg, Florida
Lineagen, Inc., Salt Lake City, Utah
MONITOR-it S.A., Esch-sur-alzette, Luxembourg
NovaScan, Milwaukee, Wisconsin
Noxilizer, Inc, Baltimore, Maryland
Oncoscope, Inc, Durham, N. Carolina
Photo Dynamic Therapy LLC, Vienna, Austria
Profound Medical Inc., Toronto, Ontario, Canada
Regenesis Biomedical Inc, Scottsdale, Arizona
S.E.A. Medical Systems, Inc, Santa Clara, California
Semprus BioSciences, Cambridge, Massachusetts
SendSor Group, Lafayette, Indiana
Sphere Medical, Cambridge, United Kingdom
Tissue Fusion, LLC, Colorado Springs, Colorado
TrusTech, Manchester, England
ValveXchange, Inc., Aurora, Colorado
ZSX Medical, LLC, King of Prussia, Pennsylvania
In addition to the companies listed above, from 2:50 p.m. to 4:50 p.m. Tuesday, October 19, the Coulter Foundation Translational Research Partnership Universities -- Boston University, Case Western Reserve University, Duke University, Georgia Institute of Technology and Emory University, Stanford University, University of Michigan, University of Maryland, University of Virginia, University of Washington and University of Wisconsin -- will present 20 innovative and exciting advances solving pressing, unmet clinical needs. These presentations will focus on advances in the following areas -- cardiovascular, IVD diagnostics, imaging, neurology, ophthalmology, orthopedics, surgical tools, tissue regeneration and wound healing.
"To further assist emerging growth companies and foster innovation, AdvaMed 2010 will host two funding forums on Tuesday, October 19," said Mr. Richard Holdren, a Texas-based angel investor with Healthcare Angels and AdvaMed 2010 Business Development Committee member. The two forums are titled "Tap Into $2 Billion in Government Funding" and "Venture Funding." "These forums will focus on the SBIR and STTR federal small business grant and contract programs and today's venture capital investment environment," Holdren said.
Pete Shagory, Principal with Baird Venture Partners will lead the Venture Funding forum. Both the National Venture Capital Association and the Angel Capital Association support AdvaMed 2010: The MedTech Conference activities.
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.AdvaMed.org.
About AdvaMed 2010:
AdvaMed 2010 is the premier MedTech conference for business leaders, entrepreneurs, policymakers, media, financiers, and other industry stakeholders from around the world. In its second year, AdvaMed 2009 attracted 1,400 plus industry leaders – including 500+ CEOs, Presidents and C-level executives.
In today's economic and political climate, AdvaMed 2010 is this year's can't miss MedTech event for networking; conducting partnering meetings; influencing policymakers and the media; and participating in educational sessions. Whether you need to finance, partner, or license technology; learn the latest important developments in reimbursement, regulatory, legal, intellectual property, and other critical areas; or meet with and hear from leaders in the Obama Administration and Congress, AdvaMed 2010 is your introduction to key decision-makers. For more information, visit www.AdvaMed2010.com.
SOURCE AdvaMed; AdvaMed 2010